Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Eisai Inc.
- 入组人数
- 135
- 主要终点
- Time to progression: RECIST (Response Evaluation Criteria in Solid Tumors) criteria
研究概览
简要总结
The purpose of this study is to assess the efficacy and safety of irofulven-based regimens compared to mitoxantrone plus prednisone in patients with hormone-refractory prostate cancer (HRPC) whose disease has progressed following Taxotere based regimens.
详细描述
For every five patients randomized, two will receive treatment number 1 (irofulven + prednisone), two patients will receive treatment number 2 (irofulven + capecitabine (Xeloda®) + prednisone), and one patient will receive treatment number 3 (mitoxantrone + prednisone). This is not a blinded study, so both the patient and doctor will know which treatment has been assigned.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •To be included in the study, patients must meet the following criteria:
- •Cancer of the prostate confirmed by a biopsy sample.
- •18 years of age or older.
- •Disease must have spread beyond the prostate as proven by chest x ray, abdominal and pelvic computed tomography (CT) scan, bone scan or clinical examination.
- •At least one prior hormonal treatment with documented disease progression during hormone therapy.
- •One previous line of chemotherapy that included Taxotere® (as monotherapy or in combination). This could be in addition to estramustine single agent therapy.
- •Disease progression during prior Taxotere-based therapy or within 3 months of discontinuing.
- •Recovered from any toxic effects of prior chemotherapy, radiotherapy and surgery.
- •Recovered from any toxic effects associated with other investigational drugs, if applicable.
- •Signed informed consent obtained prior to initiation of any study-specific procedures or treatment.
排除标准
- •Patients cannot participate in the study if any of the following apply:
- •Unable to use prednisone.
- •Prior treatment with irofulven, capecitabine (Xeloda), continuous/protracted infusion 5-FU (5-fluorouracil) (infusion duration greater than or equal to 24 hours), other fluoropyrimidines or mitoxantrone.
- •Ongoing treatment with a corticosteroid at a prednisone-equivalent dose > 10 mg/day.
- •More than 1 prior treatment with either 153Sm or 89Sr, or radioisotope treatment within 8 weeks prior to entering this study.
- •Initiation of treatment with bisphosphonate agents (e.g., pamidronate, etidronate) within 2 months of entering the study. Pre-existing treatment with bisphosphonate agents is to be continued during this study.
- •Treatment with warfarin and/or phenytoin within 14 days before entering this study or during the study period.
- •Please note: There are additional inclusion/exclusion criteria. The study center will determine if patients meet all of the criteria. If patients do not qualify for the trial, study personnel will explain the reasons. If patients do qualify, study personnel will explain the trial in detail and answer any questions. Patients can then decide if they wish to participate.
研究组 & 干预措施
3
Mitoxantrone + prednisone
干预措施: Prednisone (Drug)
1
Irofulven + prednisone
干预措施: Irofulven (Drug)
1
Irofulven + prednisone
干预措施: Prednisone (Drug)
2
Irofulven + capecitabine + prednisone
干预措施: Prednisone (Drug)
2
Irofulven + capecitabine + prednisone
干预措施: Capecitabine (Drug)
2
Irofulven + capecitabine + prednisone
干预措施: Irofulven (Drug)
3
Mitoxantrone + prednisone
干预措施: Mitoxantrone (Drug)
结局指标
主要结局
Time to progression: RECIST (Response Evaluation Criteria in Solid Tumors) criteria
时间窗: Between randomization and study discontinuation or disease progression, whichever occurs later.
Time to progression: Prostate-specific antigen (PSA) evolution (Prostate-Specific Antigen Working Group Recommendations [PSAWGR criteria]).
时间窗: Between randomization and study discontinuation or disease progression, whichever occurs later.
次要结局
- Assess pain response in patients with significant pain at baseline using Tannock criteria and McGill-Melzack Pain Questionnaire.(Seven days prior to randomization and prior to each new cycle of study drug administration.)
- Efficacy: Overall survival; objective response rate and PSA response rate according to RECIST and PSAWGR criteria, respectively.(Between randomization and death.)
- Determine safety profile of each treatment arm: incidence and severity of adverse events (AEs), serious AEs, and laboratory abnormalities.(Between randomization until a minimum of 30 days after last dose of study drug; treatment-related AEs will be followed until resolution.)
- Quality of life (QOL) as measured by the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI).(Between baseline and study drug discontinuation.)